XTL Biopharmaceuticals Ltd. (XTLB)
1.98
-0.01
(-0.50%)
USD |
NASDAQ |
Oct 09, 16:00
1.98
0.00 (0.00%)
After-Hours: 20:00
XTL Biopharmaceuticals Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2024 | -14.86% |
| September 30, 2024 | 28.37% |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 |
| Date | Value |
|---|---|
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 57.84% |
| June 30, 2014 | 70.26% |
| March 31, 2014 | 73.25% |
| December 31, 2013 | 75.53% |
| September 30, 2013 | 61.94% |
| June 30, 2013 | 63.28% |
| March 31, 2013 | 70.43% |
| December 31, 2012 | 62.35% |
| September 30, 2012 | 54.52% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| BioLineRx Ltd. | 53.41% |
| Kamada Ltd. | 40.91% |
| Can-Fite BioPharma Ltd. | -- |
| Eocene Ltd. | -- |
| Revium Recovery, Inc. | -- |